SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs stronger-than-expected Q3 performance and higher 2027 EBITDA outlook are driving attention, with traders pointing to stronger steel pricing and anticipating short-covering. Others caution that the outlook depends on pricing assumptions and may not resolve the companys substantial debt concerns.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a sharp neocloud selloff as traders question whether AI infrastructure providers can finance their expansion and earn adequate returns; speculation about forced fund liquidations is unconfirmed. The community is split between viewing the drop as an oversold buying opportunity, citing analyst support and insider purchases, and warning that the rebound could fade as sector financing concerns persist.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade of CoreWeave to Buy is driving a rebound after a steep selloff over financing and debt concerns. Traders are split between expecting a recovery or short squeeze and warning that the companys heavy obligations and insider selling remain significant risks.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDA-approved expansion of Alpha Taus REGAIN trial for recurrent glioblastoma, alongside planned SNO data presentation, is driving attention; traders are upbeat about the early results and a larger patient cohort, while further evidence is still pending. The community also points to upcoming pancreatic and other clinical milestones as potential catalysts.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

CEO Angelos Stergious anniversary post and next chapter language have fueled speculation among traders about imminent REGAL trial news or a buyout, though others see it as a routine anniversary message with no new information. The central focus remains the blinded Phase 3 REGAL study, last reported at 78 of 80 events; bulls interpret the prolonged wait as a possible survival signal and look to ASH, while skeptics say the delay does not reveal the outcome.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas sharp pullback is being attributed by traders to repeated insider share sales and a DBS downgrade, with frustration also focused on management not announcing a fresh buyback. The debate pits bulls who see the valuation and business growth as attractive against bears concerned about continued selling and weak price action.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Bernsteins upgrade of Datadog to Outperform, citing AI-driven demand for its observability offerings, is drawing attention as shares rebound. Traders are weighing that bullish AI-growth case against concerns about the stocks rich valuation and recent software-sector volatility.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

Attention centers on Amazon-backed X-Energy and AEP studying a 12-reactor, 960-MW Xe-100 project in Indiana, reinforcing the long-term data-center power theme. Traders see Amazons backing as a reason to buy the dip, while others remain cautious amid the selloff and note that the project is still exploratory.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on the Dows choppy performance and shifting strength versus tech-heavy indexes, with traders split between expecting rallies and warning of a correction. Treasury yields, inflation and Fed concerns, and oil-related geopolitical risks are recurring sources of market anxiety.

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Dynex Capital, Inc.

Dynexs Q3 results have put pressure on shares, with traders focused on a sharp book-value decline driven mainly by wider agency mortgage spreads and earnings that did not cover the dividend. The debate is between concern over the balance-sheet hit and dividend sustainability versus optimism that improving earnings and expanded Agency MBS holdings could benefit from a spread recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In 

Equity

Humacyte, Vera, Maze and Climb Bio will present dialysis-access and kidney-disease findings at ASN Kidney Week.

Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?

NKTR advances rezpeg into phase III studies for atopic dermatitis, with additional autoimmune indications offering potential growth amid stiff competition.

Here's Why You Should Add EYPT Stock to Your Portfolio Now

EyePoint's Duravyu faces a key LUCIA study data readout in late 2026, with results potentially paving the way for an NDA filing in 2027.

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?

Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.

Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month

The firm’s Pasatru drug was approved by the FDA in August, after trial results showed at least a 90% reduction in new abnormal bone lesions after 56 weeks.

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Regeneron (REGN) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD

BAYRY's Kerendia label expansion moves forward as FDA accepts an application for CKD patients without diabetes.

Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals

Biotech companies this week spent on experimental therapies, including autoimmune drugs, next-generation obesity pills and cancer combinations.

Sanofi, Regeneron Expand Immunology Alliance With New Antibodies

SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Bearish Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$MRNA" data-symbol-id="MRNA" href="https://stocktwits.com/symbol/MRNA" target="_blank">Moderna</a> and Merck will present Phase 3 melanoma findings on Saturday for their personalized cancer treatment combined with Keytruda.</li><li>Arcus will share Casdatifan kidney-cancer data on Tuesday, while Achieve presents yearlong smoking and vaping cessation findings.</li><li>TG Therapeutics and Kyverna will present CAR-T findings in neurological diseases, including progressive multiple sclerosis.</li></ul><p>The biotech spotlight will move from kidney cancer to Huntington’s disease and personalized cancer treatment this week, as Arcus Biosciences (RCUS), Alnylam (ALNY), Moderna (MRNA) and Merck (MRK) deliver clinical updates amid a busy schedule of earnings and medical conferences.</p><p>The<a href="https://stocktwits.com/symbol/XLV">&nbsp;Health Care Select Sector SPDR Fund (XLV)</a> gained 3% last week, outperforming the<a href="https://stocktwits.com/symbol/SPY">&nbsp;SPDR S&amp;P 500 ETF Trust (SPY)</a>, which fell 2%, and the<a href="https://stocktwits.com/symbol/QQQ">&nbsp;Invesco QQQ Trust (QQQ)</a>, down 6%. The<a href="https://stocktwits.com/symbol/IBB">&nbsp;iShares Biotechnology ETF (IBB)</a> declined 2.2%, trailing SPY but holding up better than QQQ, while the<a href="https://stocktwits.com/symbol/XBI">&nbsp;SPDR S&amp;P Biotech ETF (XBI)</a> dropped 6%.</p><p><img src="https://news.stocktwits-cdn.com/pharma_pulse_14c016fc9d.png" alt="pharma pulse.png"></p><p>&nbsp;</p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/Event</td><td>Development</td></tr><tr><td>Oct.19</td><td>EPRX / UEG Week</td><td>Oral presentation on tissue changes following EP-104GI treatment in eosinophilic esophagitis</td></tr><tr><td>Oct.19</td><td>IMTX / TNGX / ORIC</td><td>Scheduled publication of regular ESMO abstracts</td></tr><tr><td>Oct.20</td><td>RCUS</td><td>New ARC-20 Casdatifan kidney-cancer finding and investor event&nbsp;</td></tr><tr><td>Oct.20</td><td>ACHV / CHEST</td><td>Presentation of 52-week ORCA-OL Cytisinicline efficacy data</td></tr><tr><td>Oct.20</td><td>RGNX</td><td>Sura-vec wet-AMD investor event&nbsp;</td></tr><tr><td>Oct.21</td><td>ABT / DHR / TMO</td><td>Q3 results</td></tr><tr><td>Oct.21</td><td>KYTX / IMUX</td><td>Stiff person syndrome and progressive MS presentations</td></tr><tr><td>Oct.22</td><td>RHHBY / ARGX</td><td>Roche’s quarterly sales update and Argenx’s results</td></tr><tr><td>Oct.22</td><td>VERA / HUMA</td><td>Origin 3 kidney-disease analysis and interim Phase 3 dialysis-access findings</td></tr><tr><td>Oct.22</td><td>TGTX / ZBIO</td><td>Briumvi, Obexelimab and Orelabrutinib presentations</td></tr><tr><td>Oct.23</td><td>ALNY / TGTX / KYTX</td><td>Huntington’s disease and progressive-MS clinical updates</td></tr><tr><td>Oct 23</td><td>TNGX</td><td>Pancreatic-cancer investor webcast</td></tr><tr><td>Oct.23</td><td>IMTX / BHVN / CATX</td><td>Early-stage cancer-treatment presentations at ESMO</td></tr><tr><td>Oct.24</td><td>MRNA / MRK / CMPX / IMTX</td><td>Melanoma, biliary tract cancer and Prame-program findings</td></tr><tr><td>Oct.24</td><td>VERA / MAZE / CLYM</td><td>Clinical presentations at ASN Kidney Week</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>Arcus And Achieve Lead Early Data Watch</strong></h2><p>Arcus Biosciences (RCUS) will present kidney-cancer findings on Tuesday from its ARC-20 study of Casdatifan. The update covers initial treatment combinations: Casdatifan plus Cabozantinib in 43 previously treated patients, and Casdatifan alone in 121 more heavily treated patients. Median follow-up is about 21 months for the Cabozantinib combination and 28 months for Casdatifan alone.</p><p>Achieve Life Sciences (ACHV) will present year-long Cytisinicline findings on Tuesday at CHEST in Phoenix. The ORCA-OL study enrolled 475 adults who smoked or vaped and received the drug alongside behavioral support. Results include lab-confirmed measures of quitting. Achieve plans to resubmit its smoking-cessation application in the fourth quarter after a June FDA rejection that the company said concerned manufacturing and labeling, with no clinical efficacy or safety deficiencies identified.</p><p>Eupraxia Pharmaceuticals (EPRX) will present on Monday at UEG Week in Barcelona on tissue changes following EP-104GI treatment for eosinophilic esophagitis, an inflammatory condition that can make swallowing difficult. The findings come from the early, open-label Resolve study, while interim results from its randomized Phase 2b portion are expected in December.</p><p>RegenXBio (RGNX) will review its sura-vec treatment for wet age-related macular degeneration at a Tuesday investor event ahead of trial results expected in the fourth quarter.</p><h2 class="st-heading-2"><strong>Roche And Argenx Take Results Spotlight</strong></h2><p>Roche (RHHBY) will report third-quarter sales on Thursday. First-half sales grew 6%, excluding currency effects but fell 2% in Swiss francs. Growth was led by Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo.</p><p>Argenx (ARGX) also reported on Thursday, following positive Phase 2 findings for its celiac-disease treatment FB102 and its decision to stop its Phase 3 Sjogren’s disease trial after an interim analysis indicated it was unlikely to succeed. Abbott (ABT), Danaher (DHR) and Thermo Fisher Scientific (TMO) report on Wednesday.</p><h2 class="st-heading-2"><strong>Neurological CAR-T Studies In Focus</strong></h2><p>TG Therapeutics (TGTX) will present its first Phase 1 Azer-cel results in primary progressive multiple sclerosis (MS) on Friday at MSToronto2026, with the full abstract due Wednesday. The treatment uses genetically modified donor immune cells. Other presentations cover seven-year Briumvi outcomes, findings from routine care and a simplified initial dosing schedule.</p><p>Kyverna Therapeutics (KYTX) will present one-year Phase 2 Kysa-8 findings for miv-cel in stiff person syndrome on Wednesday, followed by updated results from a physician-led Phase 1 study in progressive MS on Friday.</p><p>Immunic (IMUX) will share longer-term progressive-MS findings from Calliper on&nbsp; Wednesday. Zenas BioPharma (ZBIO) follows on Thursday with Phase 2 MS findings for Obexelimab and Orelabrutinib.</p><h2 class="st-heading-2">Huntington’s And Cancer Data Close Trading Week</h2><p>Alnylam Pharmaceuticals (ALNY) will present initial Phase 1 ALN-HTT02 results on Friday at the European Huntington’s Disease Network congress in Krakow. Developed with Regeneron, the investigational RNA-interference treatment targets huntingtin, the protein implicated in Huntington’s disease.</p><p>Tango Therapeutics (TNGX) will hold a pancreatic-cancer webcast on Friday discussing Vopimetostat combined with Daraxonrasib or Zoldonrasib. The study involves patients with MTAP-deleted, RAS-mutant cancers.&nbsp;</p><h2 class="st-heading-2"><strong>Kidney Week Puts HUMA And VERA In Focus</strong></h2><p>Humacyte (HUMA) will present interim Phase 3 V012 results on Thursday, comparing its tissue-engineered vessel with a conventional fistula for dialysis access in women with end-stage kidney disease. The company targets a supplemental FDA application this quarter.</p><p>Vera Therapeutics (VERA) will present its Origin 3 final efficacy analysis on Thursday, following the September announcement of the results. Saturday brings separate interim Phase 2 Pioneer findings in IgA nephropathy and primary membranous nephropathy.</p><p>Maze Therapeutics (MAZE) presents additional detail from its previously reported Phase 2 Horizon kidney-disease study on Saturday. Climb Bio (CLYM) presents healthy-volunteer CLYM116 findings on Thursday and preliminary Phase 2 Budoprutug results in primary membranous nephropathy on Saturday.</p><h2 class="st-heading-2"><strong>Moderna And Merck Lead ESMO’s Saturday Watchlist</strong></h2><p>ESMO opens on Friday in Madrid. Moderna (MRNA) and Merck (MRK) will present Phase 3 INTerpath-001 melanoma findings on Saturday, testing individualized treatment intismeran autogene plus Keytruda against Keytruda alone after surgery.</p><p>The companies previously announced improvements in recurrence-free and distant-metastasis-free survival. Overall-survival evaluation continues. Moderna will also host an investor webcast on Saturday.</p><p>Compass Therapeutics (CMPX) presents Companion-002 findings on Saturday. Tovecimig plus Paclitaxel improved response rates and progression-free survival in previously treated biliary tract cancer, but did not demonstrate a statistically significant overall-survival benefit. Compass says the FDA recommended another trial demonstrating a survival benefit before an application.</p><p>Immatics (IMTX) presents IMA203CD8 cell-therapy findings on Friday, followed Saturday by IMA402 bispecific data and Anzu-cel melanoma follow-up. Biohaven (BHVN), Perspective Therapeutics (CATX) and Eikon Therapeutics (EIKN) also have early-stage cancer presentations on Friday.</p><p>Additional presentations include Incyte’s (INCY) CDK2-inhibitor findings on Friday and colorectal-cancer bispecific data on Saturday, alongside Regeneron’s (REGN) final Phase 2 analysis of Cemiplimab before surgery in cutaneous squamous-cell carcinoma on Saturday.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-musk-tesla-value-optimus-cybercab-analyst-flying-halo-car-luring-buyers/cZx8eXmRBtv">TSLA Stock Rises Overnight: Musk Bets Tesla’s Value On Optimus, Cybercab — Analyst Sees Flying ‘Halo Car’ Luring Buyers&nbsp;</a></p>

In this photo illustration, silhouette of hands in medical gloves hold a medical syringe and a vial in front of Pfizer,Biontech,AstraZeneca,Moderna,Johnson & johnson,Novavax,Merck and Janssen logos. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In

iShares Biotechnology ETF

Merck & Co Inc

Moderna Inc

Regenxbio Inc

TG Therapeutics Inc

Tango Therapeutics Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Track REGN stock price, charts, news and real-time market activity on Stocktwits. Join the REGN message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Regeneron Pharmaceuticals, Inc stock.

REGN Stock Price Today - Regeneron Pharmaceuticals Inc News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

REGN News